Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.71 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.71 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.71 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.71 |
| ▸ | AHCY | P23526 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.59 |
| ▸ | AMD1 | P17707 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | GAPDH | P04406 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16141172 | 1.00 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL23120996 | 1.00 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL13435086 | 1.00 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL13623625 | 1.00 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL19953837 | 1.00 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL24450953 | 0.87 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL16976156 | 0.86 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL15381063 | 0.86 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL9940772 | 0.84 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL12928304 | 0.84 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2990410-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | Alnylam Pharmaceuticals Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20150232840-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS | 2015-08-20 | — | — | US | disclosed |
| EP-1791567-B1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | BANK OF AMERICA, N.A. | 2015-07-09 | — | — | US | disclosed |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | BANK OF AMERICA, N.A. | 2015-07-09 | — | — | US | disclosed |
| US-8957223-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957223-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8927520-B2 | Antibacterial compounds | INSTITUT PASTEUR (FR) | 2015-01-06 | — | — | US | disclosed |
| US-8017763-B2 | Chemically modified oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110027882-A1 | Methods and Compositions for Treating Neurological Disease | UNIVERSITY OF MASSACHUSETTS | 2011-02-03 | — | — | US | disclosed |
| US-20110027882-A1 | Methods and Compositions for Treating Neurological Disease | UNIVERSITY OF MASSACHUSETTS | 2011-02-03 | — | — | US | disclosed |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS (US) | 2010-10-21 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7465544-B2 | Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070161007-A1 | Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | MASSACHUSETTS, UNIVERSITY OF | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | PI4KA 2920/4885PI4K2B 2760/4885PI4K2A 1658/4885 |
| US-20150232840-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | PI4KA 2920/4885PI4K2B 2760/4885PI4K2A 1658/4885 |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | PI4KA 3823/4885PI4K2B 3811/4885PI4K2A 3642/4885 |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | PI4KA 2920/4885PI4K2B 2760/4885PI4K2A 1658/4885 |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | PI4KA 2920/4885PI4K2B 2760/4885PI4K2A 1658/4885 |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | PI4KA 3823/4885PI4K2B 3811/4885PI4K2A 3642/4885 |
| US-20070161007-A1 | Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use | DNMT1, MAT2A, MAT1A | PI4KA 2765/4885PI4K2B 3089/4885PI4K2A 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.